Neuroblastoma is the most common extracranial solid tumour in children accounting for 15% of all paediatric cancer deaths. High risk patients are given an intensive multi modal treatment, including high dose chemotherapy, radiation therapy and surgical resection of the tumour. Despite this, less than 40% of high risk patients survive, and those that do have long term chronic conditions due to the toxicities associated with these conventional therapies. Immunotherapies such as adoptive T cell therapy (ACT) aim to strengthen the host’s immune system to recognise and kill cancer cells. Understanding the tumour microenvironment and the associated immune response is crucial for improving the efficacy of ACT. In this study we optimised a pre-clinical subcutaneous model of neuroblastoma,characterised the immune cells present in the tumour microenvironment and systemically throughout the host. First, we determined the optimal number of neuroblastoma cells required for consistent tumour growth and development in our model. We used flow cytometry to analyse immune cells present in both tumour tissue and lymphoid organs using optimised myeloid and lymphoid panels. Finally, we examined the therapeutic potential of an ACT protocol for neuroblastoma. This allowed us to assess the efficacy of tumour specific T cells in vivo and understand the limitations of this treatment. Anticipated outcomes include the development of a pre-clinical immunocompetent model of neuroblastoma, allowing identification of new targets for immune-based therapies for neuroblastoma in combination with ACT.